| US 7,563,895 B2 | ||
| Quinoxaline compounds | ||
| Brett D. Allison, Del Mar, Calif. (US); Michael D. Hack, San Diego, Calif. (US); Victor K. Phuong, San Diego, Calif. (US); Michael H. Rabinowitz, San Diego, Calif. (US); and Mark D. Rosen, San Diego, Calif. (US) | ||
| Assigned to Janssen Pharmaceutica, N.V., (Belgium) | ||
| Filed on Dec. 04, 2007, as Appl. No. 11/950,326. | ||
| Application 11/950326 is a division of application No. 10/910925, filed on Aug. 04, 2004, granted, now 7,304,051. | ||
| Claims priority of provisional application 60/494074, filed on Aug. 08, 2003. | ||
| Prior Publication US 2008/0076918 A1, Mar. 27, 2008 | ||
| Int. Cl. C07D 241/4237 (2006.01) | ||
| U.S. Cl. 544—353 [514/249] | 2 Claims |
1. A compound useful in the production of amidophenyl-sulfonylamino-quinoxalines of the general formula:
 Ra is independently selected from the group consisting of C1-6alkyl, C2-6alkenyl, C3-6cycloalkyl, phenyl, furanyl, thienyl, benzyl, pyrrol-1-yl, —OH, —OC1-6alkyl, —OC3-6cycloalkyl, -Ophenyl, -Obenzyl, —SH, —SC1-6alkyl, —SC3-6cycloalkyl, Sphenyl, -Sbenzyl, —CN, —NO2, —N(Ry)Rz (wherein Ry and Rz are independently selected from H, C1-4alkyl or C1-6cycloalkylC1-4alkyl), —(C═O)C1-4alkyl, —SCF3, halo, —CF3, —OCF3, and —COOC1-4alkyl, or, alternatively, two adjacent Ra, may be taken together with the carbons of attachment to form a fused ring and selected from the group consisting of phenyl,
pyridyl and pyrimidinyl;
or alternatively, R2 and one of Ra can be taken together to be —CH2— or >C═O and to form a fused ring to the phenyl;
Rb is, independently, selected from the group consisting of C1-4alkyl and halogen;
and enantiomers, diastereomers, hydrates, solvates and pharmaceutically acceptable salts, esters and amides thereof.
|